Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SpaceXs rally is being linked by traders to Morgan Stanleys bullish view and anticipation of Starship Flight 15, with the proposed SpaceXAI-to-SpaceXSI rebrand and AI ambitions adding to the enthusiasm. Bulls point to breakout momentum and possible short covering, while skeptics argue the valuation is stretched and cite upcoming share unlocks.

Novavaxs sharp move is drawing attention amid reports of a suspected plague outbreak in Russia, with traders speculating about renewed pandemic-related vaccine demand and a short squeeze. Others argue the outbreak is not a direct catalyst and point instead to the companys vaccine-partner news, while cautioning that the rally may be driven by hype and could reverse.

Evernorths approved merger with Armada and planned Nasdaq debut are driving attention, with the companys XRP-treasury strategy drawing comparisons to other crypto treasury plays. Traders are debating whether the sharp, volatile run reflects durable demand or a low-float SPAC squeeze, while also focusing on warrant pricing and potential dilution.

AAOI is drawing attention as traders react to reports that its at-the-market share-sale program is complete, easing a perceived source of selling pressure amid a rebound. Bulls point to AI data-center demand for optical transceivers and expansion plans, while skeptics remain concerned about dilution, execution, and the stocks sharp volatility.

GRRR is under pressure amid uncertainty over how it will finance its large AI-infrastructure projects, with traders focused on potential dilution and whether announced contracts will translate into revenue and cash flow. Bulls point to reported project progress and contract demand, while skeptics say management needs to provide clearer financing details and execution evidence.

Capricors 24-month HOPE-3 extension data showing slower upper-limb decline in Duchenne muscular dystrophy patients has renewed focus on deramiocels FDA review. Despite the encouraging results, traders are debating whether they overcome concerns about the original trials statistics; a skeptical analysts continued expectation of a rejection has coincided with a sharp selloff, while bullish traders view the data as supportive of approval.

Amazons reported plan to move roughly $8 billion in Nvidia chips into an outside-investor vehicle and lease them back has fueled debate over its AI infrastructure spending: some traders view it as balance-sheet financing while the chips remain in use, while others see a warning about capex and financing risks. That discussion sits alongside frustration with AMZNs choppy, lagging share performance despite bullish views on AWS and AI demand.

Vaxcytes VAX-31 met the primary endpoints in its pivotal Phase 3 OPUS-1 trial in adults, boosting optimism that the pneumococcal vaccine could compete with established products and sending shares sharply higher. Traders are debating the rallys durability, with profit-taking, short bets, and concerns about a proposed stock-and-convertible-notes offering weighing against the positive data.

A bullish Jefferies initiation and optimism about Aehrs AI-chip testing demand have fueled attention, with traders also pointing to customer orders and an anticipated revenue ramp. The community is split between seeing more upside from the AI opportunity and warning that the valuation is stretched, insider selling is concerning, and the shares remain highly volatile.

MELI is drawing attention after Brazil election results sparked a rally across Brazilian and Latin American stocks; traders attribute the move to expectations around Flvio Bolsonaros strong showing rather than company-specific news. Some see the regional surge as a potential turning point, while others question whether the political news justifies the size of the jump.